Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older

Lucie Oberic,Frédéric Peyrade,Mathieu Puyade,Christophe Bonnet,Peggy Dartigues-Cuillères,Bettina Fabiani,Philippe Ruminy,Hervé Maisonneuve,Julie Abraham,Catherine Thieblemont,Pierre Feugier,Gilles Salles,Fontanet Bijou,Gianmatteo Pica,Gandhi Damaj,Corinne Haioun,René-Olivier Casasnovas,Hassan Farhat,Ronan Le Calloch,Agathe Waultier-Rascalou,Sandra Malak,Jérôme Paget,Elodie Gat,Hervé Tilly,Fabrice Jardin

Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older

2021

PURPOSE:The prognosis of elderly patients with diffuse large B-cell lymphoma (DLBCL) is worse than that of young patients. An attenuated dose of chemotherapy—cyclophosphamide, doxorubicin, vincrist...

Keywords:

Oncology
Internal medicine
Lenalidomide
Lymphoma
Diffuse large B-cell lymphoma
Doxorubicin
Rituximab
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations